Conjugated Linoleic Acid (CLA) — Research Profile

CLA reduces body fat rather than total weight. A meta-analysis of 18 RCTs showed ~0.05 kg/week of fat loss ^[1], which translates to about 1 kg of fat over 5 months beyond what diet alone achieves. This is modest but consistent. Don't expect dramatic weight loss — CLA is a long-term body composition supplement, not a rapid weight loss solution.

Most studies show measurable body fat reduction after 6-12 weeks of consistent use at 3.2+ g/day. The Gaullier 12-month study showed continued benefits over a full year. CLA works gradually — commit to at least 3 months before evaluating results.

At standard doses (3.2-3.4 g/day), CLA is generally well tolerated. Some concerns exist: the t10,c12 isomer may worsen insulin sensitivity in some people, and some studies show increased CRP (an inflammatory marker). These effects are typically mild. Monitor blood sugar if diabetic.

CLA is sold as a mixed-isomer oil, and the two chemical forms compared head-to-head over 1 year, free-fatty-acid and triacylglycerol, both reduced body fat, so neither is clearly superior for that outcome. In the same trial the free-fatty-acid form raised LDL while the triacylglycerol form lowered HDL, so the practical choice comes down to tolerability rather than any proven advantage.

The one reasonably supported benefit is a modest reduction in body fat: at about 3.2 g/day CLA lowered fat mass by roughly 0.09 kg per week versus placebo in pooled trials, and a meta-analysis of studies 6 months or longer found about 0.7 kg more weight loss and 1.3 kg more fat loss than placebo, though the authors judged the clinical relevance uncertain. Adding CLA to exercise modestly improved fat loss and insulin resistance. Claims of large weight loss or broad metabolic improvement are not supported.

Most trials used about 3.2 g/day of CLA, the median dose in the largest human meta-analysis, usually split across meals. That meta-analysis found a modest dose-response, roughly an extra 0.024 kg of fat lost per week for each additional gram per day, and higher doses of about 6 g/day have been tested safely for up to a year. No official dose is established, and larger amounts mainly add gastrointestinal upset and unfavorable lipid changes rather than a proportionate benefit.

No study has directly compared times of day for CLA, so none is proven better. As a fat-soluble oil it is typically taken with meals, and splitting the daily amount across meals is the pattern used in most trials, which may also ease the stomach upset that is CLA's most common side effect.

The most common complaints are gastrointestinal: upset stomach, nausea, constipation, diarrhea, or soft stools. Beyond the gut, CLA can shift blood lipids unfavorably, significantly lowering HDL cholesterol in pooled trials. Reassuringly, liver enzymes (ALT and AST) did not change across trials, and the oxidative-stress marker malondialdehyde actually decreased.

Interaction data are limited, but safety references advise caution when combining CLA with blood thinners or antiplatelet drugs, diabetes medications, and cholesterol- or triglyceride-lowering medicines, noting that these interactions are not fully understood. Because CLA can lower HDL cholesterol in pooled trials, its lipid effect may run counter to the goals of lipid-lowering therapy, so tell your prescriber before combining them.

CLA is aimed at overweight adults (BMI 25 or above) seeking a modest boost to fat loss, and its effects are most consistent when paired with exercise and, in one analysis, among women. Its effects during pregnancy and breastfeeding are unknown, so it is best avoided then and kept away from children. People with diabetes or obesity should be cautious because of a possible pro-oxidant effect at supplement doses, and anyone on lipid-lowering or blood-sugar medicines should check with a clinician first.

CLA acts slowly, not acutely. In a meta-analysis of 18 human trials the fat-loss effect was roughly linear for the first ~6 months and then flattened toward 2 years, so most controlled studies ran 6-12 months before measuring meaningful change. Even then the effect was modest, about 0.09 kg of fat lost per week versus placebo, so expect gradual change over months rather than weeks.

In the longest controlled trials, CLA was given to overweight or obese adults for a full year with no more adverse events than placebo, and one 12-month safety trial actually reported fewer adverse events on CLA than placebo. Over that year, however, LDL cholesterol rose in one CLA group, HDL fell in another, and lipoprotein(a) increased in both, while fasting glucose stayed unchanged. A meta-analysis of trials lasting 6 months or longer judged the body-composition benefit small and of uncertain clinical relevance, and consumer references flag a possible pro-oxidant effect at supplement doses, especially in people with diabetes or obesity. Safety much beyond about a year has not been well studied.

No tolerable upper limit has been established for CLA. Most trials used a median of about 3.2 g/day, and higher doses of roughly 6 g/day have been tested for up to a year without excess adverse events. The main concern with larger intakes is not acute toxicity but the unfavorable lipid shifts seen with year-long dosing, such as lower HDL cholesterol and higher lipoprotein(a), so pushing the dose adds risk without a clearly proportionate benefit.

The best-studied pairing is CLA plus exercise: a meta-analysis found the combination reduced body fat more than exercise alone (SMD -0.42) and slightly improved insulin resistance, though it added nothing to body weight, exercise performance, or blood lipids. Evidence for stacking CLA with other supplements is thin, and because CLA tends to lower HDL cholesterol, combining it with other agents that shift lipids has no proven advantage.

Check the label for the actual CLA content rather than total oil weight, since most positive trials delivered about 3.2 g/day of CLA itself. Choose a standardized mixed-isomer product; the Clarinol oil used in the 12-month human safety trial is one such preparation. In the year-long body-fat trial, the free-fatty-acid and triacylglycerol forms both reduced fat mass, so verified CLA content and third-party purity matter more than the specific chemical form.